Health and Fitness Health and Fitness
Thu, January 13, 2011
Wed, January 12, 2011
Tue, January 11, 2011
Mon, January 10, 2011
[ Mon, Jan 10th 2011 ] - Market Wire
Teleflex Acquires VasoNova Inc.
[ Mon, Jan 10th 2011 ] - Market Wire
30 A.M. ET
Sun, January 9, 2011
Fri, January 7, 2011
Thu, January 6, 2011
Wed, January 5, 2011
Tue, January 4, 2011
Mon, January 3, 2011
Fri, December 31, 2010
Thu, December 30, 2010
Wed, December 29, 2010
Tue, December 28, 2010
Mon, December 27, 2010
Fri, December 24, 2010
Thu, December 23, 2010
Wed, December 22, 2010
Tue, December 21, 2010
Mon, December 20, 2010
Fri, December 17, 2010
Thu, December 16, 2010
Wed, December 15, 2010
Tue, December 14, 2010

ImmunoGen, Inc. Announces Webcast of Presentation at J.P. Morgan 29th Annual Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. -p-morgan-29th-annual-healthcare-conference.html
Published in Health and Fitness on Monday, January 3rd 2011 at 4:20 GMT by Market Wire   Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that President and CEO, Daniel Junius, will present at the J.P. Morgan 29th Annual Healthcare Conference at 9:00 am PT/12:00 noon ET on January 10, 2011. The presentation will contain an update on IMGN901 development plans, including current plans related to Merkel cell carcinoma.

A live webcast of the presentation can be accessed through the aInvestor Informationa section of the Companya™s website, [ www.immunogen.com ]; a replay of the presentation will be available at the same location for two weeks.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGena™s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].


Publication Contributing Sources